Hypertension in CKD Market Size to Exceed USD 634.2 Mn by 2032

The Hypertension in CKD Market, estimated at USD 311.3 Mn in 2025, is expected to exhibit a CAGR of 10.7% and reach USD 634.2 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Key market players are focusing on adopting growth strategies such as collaboration, acquisition, and merger to develop and launch new products, which will drive the global hypertension in CKD market. For instance, on January 9, 2023, AstraZeneca plc, a science-led global biopharmaceutical company, announced an agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company. The acquisition will support cardiorenal pipeline by adding CinCor Pharma, Inc. candidate drug baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension in CKD.

Global Hypertension in CKD Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization has declared it a public health emergency. As the COVID-19 cases are surging, the risk for patients acquiring chronic kidney disease is also increasing. For instance, according to a study conducted in May 2020 by the researchers at Mount Sinai Health System in New York City, U.S., the occurrence of kidney disease might increase as a post-COVID-19 effect in most of the COVID-19-positive patients. Moreover, according to the National Kidney Foundation, a study found that COVID-19-positive patients hospitalized in the span of March 11 and April 26, 2020, were likely to develop acute kidney injury (AKI) twice as often as non-COVID patients.

COVID-19 pandemic had a negative impact on the global hypertension in CKD market during the forecast period. According to the Indian Journal of Medical Sciences, on June 6, 2020, the COVID-19 pandemic has affected the conduct of clinical trials due to the unavailability of trial site staff, restrictions for travel, investigational product availability, and others. These challenges are hindrances for developing new treatments for patients suffering from hypertension with CKD.

Global Hypertension in CKD Market: Key Developments

On May 2023, AstraZeneca Plc. announced the U.S. Food and Drug Administration approval for the drug Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF), and urgent heart failure (HF) visits in adults with HF. Farxiga (dapagliflozin) is a first-in-class oral, once-daily SGLT2 inhibitor that also reduces the risk of chronic kidney disease.

On January 6, 2023, KBP Biosciences PTE. Ltd. a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, announced Ocedurenone (KBP-5074) as a potential new treatment option addressing the unmet medical need of patients with uncontrolled and resistant hypertension and advanced CKD in ASN Kidney Week-based ongoing investigation in a phase 2 clinical trial.

In April 2022, Ardelyx, a U.S.-based biotechnology company, announced the results of Phase 4 clinical trials for XPHOZAH (tenapanor), indicated for the treatment of phosphate absorption inhibitors for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. The results of these trials were positive further supporting the safety and efficacy of the XPHOZAH (tenapanor) nitiating treatment with XPHOZAH monotherapy, which enabled 63.3% of patients to achieve target sP levels ≤5.5 mg/dL. Mild to moderate diarrhea was the most commonly reported adverse event (39.9%), but only 5.0% of patients discontinued the study because of diarrhea. No new safety findings were identified in this study.

Browse 20 Market Data Tables and 28 Figures spread through 135 Pages and in-depth TOC on “Global Hypertension in CKD Market”- Forecast to 2030, Global Hypertension in CKD Market, By Drug Class (Diuretics, RAS Blockade, β-Blockers, Calcium Channel Blockers Others (α-Blockers, Vasodilators, Proteinuria, etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/hypertension-in-ckd-market-4431

Key Takeaways of the Global Hypertension in CKD Market:

The global hypertension in CKD market is expected to exhibit a CAGR of 10.7% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global hypertension in CKD market.
Among drug class, the RAS blockade segment is expected to hold a dominant position in the global hypertension in CKD market during the forecast period, owing to the key players focusing on organic strategies to start new product launches. For instance, on September 22, 2023, Boehringer Ingelheim International GmbH., a Germany-based global pharmaceutical company, and Eli Lilly and Company, a U.S.-based multinational pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for Jardiance (empagliflozin) 10 mg tablets, a sodium-glucose co-transporter 2 (SGLT2) and RAS inhibitor to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.
Among region, North America is expected to be the dominant region in the global hypertension in CKD market, this is attributed to the increasing prevalence of Kidney disease and the increased rate of cardiovascular diseases. For instance, as per the data mention in an article “Kidney Disease: The Basics” published by Natinal Kidney Foundation, Kidney disease affects an estimated 37 million people in the U.S. (15% of the adult population; more than 1 in 7 adults) and around 90% of there 37 million people are unaware about they are having the disorder.
Major players operating in the global hypertension in CKD market are Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG., C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd., KBP Biosciences Holdings Limited, Ardelyx, Reata Pharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd, Pfizer Inc., Bayer Pharmaceuticals, Inc, GSK plc.